The immune system's night watch.

In 1975, researchers at the Karolinska Institute in Stockholm were running what should have been routine control experiments. Immune cells from mice that had never been exposed to a tumor were, by every rule of the day, supposed to leave tumor cells alone — killing was thought to require prior training. Instead, the untrained cells killed on contact. Rolf Kiessling and colleagues named the mystery population "natural" killer cells, for their ability to kill naturally, without priming.^[1]

That accidental observation founded an entire branch of immunology. NK cells turned out to be a distinct lymphocyte lineage — neither T cell nor B cell — belonging to the innate immune system: the fast, built-in arm that responds within hours rather than the days an antibody response takes. A fiftieth-anniversary review published in 2026 traces the field from that Stockholm bench to today's engineered NK therapies, and the arc is remarkable: a cell dismissed for years as an experimental artifact is now the platform for some of the most closely watched clinical trials in medicine.^[2]

The key conceptual breakthrough came in the 1980s with the "missing self" hypothesis. Most immune recognition works by spotting something foreign that is present. NK cells largely do the opposite: they check every cell they touch for the molecular identity badge called MHC class I, which nearly all healthy cells display. Virus-infected cells and tumor cells often hide this badge to escape T cells — and that hiding is exactly what NK cells detect. No badge, no mercy.

In one sentence

A natural killer cell is an innate immune lymphocyte that patrols the body continuously and destroys cells that are infected, malignant, or stressed — recognized not by prior training, but by missing or altered surface signals.

An adult human carries on the order of billions of NK cells, roughly five to fifteen percent of circulating lymphocytes, turning over constantly. Their day job is surveillance. Each NK cell integrates signals from a panel of activating and inhibitory receptors as it touches neighboring cells; when the balance tips toward activation, it kills within minutes, releasing perforin — a protein that punches pores in the target's membrane — and granzymes, enzymes that enter through those pores and trigger the target's self-destruct program.^[3]

Three categories of target matter most. The first is virus-infected cells: people with rare congenital NK deficiencies suffer severe, recurrent herpesvirus infections, which is some of the clearest evidence of what the cells do for the rest of us. The second is malignant cells — the original 1975 observation. Tumors arise continuously at the single-cell level and are, in the standard model of immunosurveillance, mostly eliminated before they become clinically detectable; NK cells are part of that early elimination. The third is less famous and increasingly interesting for aging biology: senescent cells.

NK cells are also more than executioners. They secrete interferon-gamma and other cytokines that recruit and instruct the rest of the immune system, shaping the slower adaptive response. This signaling role is one reason their dysfunction shows up so broadly — and one point of genuine contact with the mesenchymal stromal cells covered elsewhere in this journal: MSCs, in inflamed tissue, are known to modulate NK cell activity as part of their general immunomodulatory program, one of several ways the two cell types occupy the same conversation even though they do very different work.^[3]

Here is the part with direct relevance to longevity medicine. NK cell numbers hold up reasonably well with age — in many studies they even rise. NK cell performance does not. Aging shifts the population toward a mature subset with reduced proliferative capacity, and the killing efficiency of individual cells declines: reduced cytotoxicity per cell, slower target binding, and blunted cytokine secretion. A detailed review by Hazeldine and Lord links this measurable decline in NK function to the documented vulnerabilities of older adults — higher rates and severity of viral infection, poorer vaccine responses, and rising cancer incidence.^[4]

With age, the problem is not that the night watch goes home. It is that the watchmen still walk the halls — and kill less efficiently when they find something.

The senescent-cell connection makes this a two-way street. Senescent cells — old, damaged cells that stop dividing but refuse to die, secreting inflammatory signals that degrade the tissue around them — display stress ligands that NK cells recognize through their activating receptor NKG2D, marking them for removal.^[5] Experimental work shows that when this NKG2D-mediated surveillance is impaired, senescent cells accumulate in tissue. So declining NK function does not just weaken defense against infection and malignancy; it plausibly accelerates the accumulation of the senescent cells that drive chronic, low-grade inflammation — the "inflammaging" explained in depth in this journal's cellular-aging article. An aging immune system and an aging body are not two separate problems.

Two lines of work explain the current excitement. The first is CAR-NK: taking the chimeric antigen receptor technology behind CAR-T cancer therapy and installing it in NK cells instead. In the landmark trial at MD Anderson, cord-blood-derived CAR-NK cells produced responses in 73 percent of patients with relapsed lymphoid cancers — and, strikingly, none of the patients developed cytokine release syndrome or neurotoxicity, the two feared complications of CAR-T.^[6] NK cells appear to bring much of the firepower with far less of the collateral damage.

The second is this year's widely reported Stanford study. Solid tumors have been NK therapy's wall: infused cells circulate in blood but penetrate tumor tissue poorly. John Sunwoo's group found that exposing donor NK cells to a precisely calibrated dose of the signaling protein TGF-β — delivered by direct contact with short-lived tumor cells — converts them into tissue-resident NK cells that infiltrate solid tumors far better, suppressing melanoma and head-and-neck tumors in mice, especially when combined with an antibody drug.^[7] Sunwoo described the conditioning as a Goldilocks problem: too little TGF-β does nothing, too much suppresses the cells, and just enough transforms them.

The honest caveat comes from the study's own senior author, who called the work proof of concept and warned against extrapolating from mice to humans. That is the right frame for the whole frontier: the biology is genuinely exciting, one human trial in blood cancers has published striking results, and everything in solid tumors remains preclinical or in early trials.

Be careful with the gap between this science and the marketplace. Engineered NK therapies — CAR-NK, tissue-resident NK — exist inside registered clinical trials at academic centers, for cancer. They are not something any clinic, in any country, can legitimately sell you today, and a provider advertising NK cell infusions as a cancer treatment outside a trial is displaying exactly the red flags described in our article on safety and vetting. TrueCell does not treat cancer, and this article should not be read as an offer to.

So why does an NK explainer belong in a regenerative-medicine journal? Two reasons. First, the aging biology is directly relevant: NK function is a measurable component of immune aging, connected through senescent-cell surveillance to the inflammaging that longevity protocols target.^[4][5] Understanding it helps a patient read their own immune panel — and the field's marketing — more intelligently. Second, NK cells sit in constant dialogue with the mesenchymal stromal cells that regenerative protocols actually use: MSCs modulate NK activity as part of the same immunomodulatory program that quiets inflamed tissue, described in the MSC explainer. The immune system is one conversation, and it helps to know the participants.

The practical takeaway mirrors the rest of this journal. The unglamorous levers on NK function — sleep, exercise, metabolic health — have real supporting literature and cost nothing. The frontier therapies are worth following and worth being honest about. And any clinic that blurs the line between the two is telling you something important about itself.